Our Services and
Partners
ACECGT Diagnostics
ACECGT Diagnostic is an accredited laboratory committed in bringing innovative solution and translating life science's technology into everyday applications.
TruCheck CTC cancer screening test is a simple blood test that enables, with high sensitivity and specificity, the early detection of cancers in asymptomatic individuals, thus reducing treatment costs and improving survival rate.
LIFE LENGTH
Life Length is the world's leading diagnostic biotech company owing an intellectual property and a proprietary platform technology, based on the measurement of telomere variables and the related trials for aging and age-related diseases.
Based in Madrid, Life Length is the most advanced accredited clinical laboratory holding an Operating License from the Spanish Agency for Medicines and Health Products, and being the only US federal laboratory in Spain.
HealthTAV® monitors the aging process. This test evaluates thxe extent to which aging is affected by lifestyle and therapeutic interventions. It also analyzes effectiveness of personalized wellness programs and compliance to them.
HealthTAV® uses our patented TAT® (Telomere Analysis Technology), the worldwide most accurate tool for the measurement of telomere length and the determination of the multiple associated variables.
ProsTAV a new telomere - based biomarker for the early diagnosis of prostate cancer. ProsTAV helps reduce by 33% the need for unnecessary biopsies.
Vita DX
Vita DX is a French accredited laboratory that specializes in bladder cancer. VitaDx offers VisioCyt test, a reliable and standardised pre-endoscopic analysis with a simple voided urine sample for the diagnosis and follow-up of patients with a non-muscle invasive bladder tumor (NMIBT).
NEOSCREEN
Neoscreen Ltd. is an ISO 15189 and 17025 accredited laboratory, for performing molecular diagnostic tests, that has specialized in Clinical Genetic tests since 2007.
Its expertise includes Carrier Screening, Cancer Predisposition, Expanded Newborn Screening, Whole Exome and Whole Genome Sequencing.
Neoscreen long standing expertise in genetic testing has been added up to its flexibility to adapt to frequent changes and needs from the medical community to updated panels and tests to improve diagnosis.
GENPATH
GenPath Diagnostics, a division of Bioreference, offers comprehensive tests and services to help diagnosis and management. GenPath provides urologists with access to a suite of diagnostic testing for a variety of urologic conditions, including prostate cancer, bladder cancer, hereditary cancers, kidney stones, and sexually transmitted infections.
GenPath offers the 4Kscore® Test, a blood test combining four prostate-specific biomarkers with important clinical factors. This tests provides a man's risk for aggressive prostate cancer if a biopsy were to be performed, and offers results that should be considered in the shared decision-making process.
SMART CELLS
Smart Cells (SC) is the UK's first private bank for cord blood and cord tissue storage. It is licensed by the Human Tissue Authority (HTA) and it has been operating since 2000. Now part of FamiCord Group, the largest cord blood bank in Europe and the third largest cord blood bank in the world with more than 700,000 cord blood collections globally.
Smart Cells has now released more samples for clinical use than any other private storage company in the UK with a 100 per cent success rate. These have been used by patients all around the world to treat a range of conditions including Cerebral Palsy, Thalassemia, Leukaemia, and HSV Encephalitis.
Leading the way by using state of the art technology, Smart Cells is the most innovative company in the field. Smart Cells only uses its own laboratories for processing using Biosafe Sepax equipment for automated volume reduction of cord blood as this is the preferred method for all public banks in the United Kingdom and around the world. Smart Cells is located near Heathrow airport in London, with 12 other laboratories in Europe. Moreover, SC has the best credit score rating when compared to other banks in the UK.
STEM CELLS: storing the stem cells of life
Smart Cells Baby - Stem cells for life
PATH GROUP
PathGroup is committed to providing diagnostic expertise, precision technologies and innovative services and relationships — all to offer clinician partners personalized information for targeted therapies that lead to the best possible patient's outcome.
Led by recognized experts in the field of molecular diagnostics and bioinformatics, PathGroup works with leading individual and contract research partners in developing platforms for improved molecular intelligence. PathGroup molecular diagnostics facility includes a dedicated CLIA validation laboratory to accelerate delivery of new tests and modalities to the physicians and the patients they treat. The portfolio includes several Hematology panels in addition to Endeavor an FDA-cleared test for Molecular Profiling for solid tumors. Endeavor includes a large panel of genes tested by Immunohistochemistry (IHC) and NGS, with a comprehensive report that helps guide clinicians toward beneficial therapies for the patient.
NATERA
Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology and women's health. Natera™ aims to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier, more targeted interventions that help lead to longer, healthier lives.
Oncology:
The oncology portfolio includes Signatera™, a personalized, tumor-informed assay optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and recurrence monitoring for patients previously diagnosed with cancer.
When to use Signatera?
- Use Signatera ctDNA testing after surgery to evaluate the need for adjuvant chemotherapy and avoid unnecessary treatment.
- Use Signatera to detect recurrence earlier, while it may still be resectable, and also to reduce false positives.
- Use Signatera during immunotherapy treatment to help evaluate treatment response.
Women's Health:
Identify risk of severe genetic conditions helping families and treating physicians prepare early intervention thus improving outcomes.
Panorama: Next-Generation NIPT (Non-Invasive Prenatal Test)
Panorama is a blood-based genetic, prenatal screening test for pregnant women analyzing common chromosomal conditions affecting their baby's health. Panorama can be performed as early as 9 weeks of pregnancy.
The only SNP-based NIPT delivering more insights with high accuracy: Panorama is:
- Validated in the largest prospective NIPT study ever
- The only NIPT that distinguishes the pregnant person's DNA from baby's DNA
- Based on the approach that creates unique and clinically validated capabilities
Panorama is based on SNPs (Single Nucleotide Polymorphism) evaluation— the 1% of human DNA that makes one person different from the another.
Horizon: a comprehensive, actionable carrier screening. Horizon helps couples determine the risk of passing on serious genetic conditions to their child. It can be performed either during preconception (ideally) or during pregnancy.
AGENDIA
As the only molecular diagnostics company solely focused on breast cancer, Agendia's groundbreaking genomic testing generates reliable and meaningful clinical data about the unique biology of a woman's breast cancer. Globally backed up by prestigious physicians and institutions, Agendia is shifting the standard of care towards more ideal, personalized treatment.
Prior to genomic profiling, treatment decisions were based solely on clinicopathologic factors - such as the patient's age, tumor grade, lymph node involvement and hormone receptor status. While important to consider, they provide a more superficial view of your patient's breast cancer.
At the genomic level, Agendia provides physicians with a tool that allows the examination of specific genes' activity inside the tumor - how they interact to drive the behavior of a tumor. By pairing these insights with clinical factors, we can more comprehensively understand a woman's unique cancer and more confidently plan her next steps.
MammaPrint is FDA-cleared (US) for women of all ages. The device is also CE marked allowing for use in the European Union.
Mammaprint test is supported by peer reviewed data and highest level of clinical evidence through prospective randomized clinical trial.
Mammaprint is recommended by international guidelines such as ESMO, San Gallen, ASCO and NCCN.
Together, our tests address two critical questions:
What are the chances her cancer returns ?
What type of cancer am I dealing with ?
Ready to embark on a journey of digital transformation?
Let's turn your vision into reality. Contact us today to set your brand on the path to digital excellence with us.